Balancing benefits and harms in health care
BMJPublished 10 July 2003Open access
Luis Gabriel Cuervo, Mike Clarke
Citations104
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Randomised controlled trials are the best way to evaluate small to moderate effects of healthcare interventions, but they are not always suitable to evaluate harms, and this was made clear during a recent meeting jointly organised by the Cochrane Collaboration and BMJ Knowledge in London.
Keywords
Decision SciencesEconomics, Econometrics and FinancePharmacology, Toxicology and Pharmaceutics
The LancetImproving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
4,808 Citations1999David Moher, Fadi Hammal +4 more
This report hopes this report will generate further thought about ways to improve the quality of reports of meta-analyses of RCTs and that interested readers, reviewers, researchers, and editors will use the QUOROM statement and generate ideas for its improvement.
New England Journal of MedicineComparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
4,017 Citations2000Claire Bombardier, Loren Laine +10 more
In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
BMC Medical Research MethodologyThe CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials
2,754 Citations2001David Moher, Kenneth F. Schulz +1 more
The revised CONSORT statement is intended to improve the reporting of an RCT, enabling readers to understand a trial's conduct and to assess the validity of its results.
BMJEfficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials
370 Citations2002Jonathan J Deeks, Lesley A Smith +1 more
Celecoxib is as effective as other NSAIDs for relief of symptoms of osteoarthritis and rheumatoid arthritis and has significantly improved gastrointestinal safety and tolerability.
BMC Medical Research MethodologyIncomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials
111 Citations2001Sheena Derry, Yoon K. Loke +1 more
Specific search strategies based on adverse effects textwords and indexing terms will fail to identify nearly a quarter of trials that report on the rate of drug adverse effects.
The LancetNSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection
70 Citations2001Maarten Boers
Fundamental and Clinical PharmacologyAdverse drug reactions: keeping up to date
50 Citations2002Jeffrey K Aronson, Sheena Derry +1 more
Although many of the randomized controlled trials are of good quality and large enough to reveal benefit, most are too small to provide robust information about adverse drug reactions and more are needed.
PubMedSquamous cell carcinoma of the skin (non-metastatic).
26 Citations2003Adèle C. Green, Penelope McBride
PubMedMalignant melanoma (non-metastatic).
9 Citations2002Philip Savage, Thomas Crosby +1 more
The incidence of malignant melanoma has increased over the past 25 years in the UK, but death rates have remained fairly constant, with greater risks in white populations and in people with higher numbers of skin naevi.